KNSA: Rega marang dodolan Kiniksa Pharmaceuticals Ltd
The P/S business valuation on the GURU.Markets dynamic chart illustrates an ecosystem for treating rare cardiovascular pathologies, where the 4.90 value characterizes this level. Kiniksa Pharmaceuticals (KNSA) is developing therapies for immune failures through partnerships with biotech institutes. Strong patents in the inflammatory heart disease niche ensure high margins and a lack of direct market equivalents.
Rincian analitis perusahaan kiniksa.com (KNSA)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Rasio Utang marang Ekuitas Kiniksa Pharmaceuticals|KNSA - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal kiniksa.com|KNSA - Utang perusahaan|Utang-utang marang kapitalisasi buku Kiniksa|KNSA - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Kiniksa|Rasio cepet kiniksa.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
KNSA - Penghasilan resik|Penghasilan resik sing dikarepake Kiniksa Pharmaceuticals|KNSA - Rasio rega marang bathi|Rasio rega marang bathi sing dikarepake Kiniksa Pharmaceuticals Ltd|KNSA - Pangali PEG|Nilai bisnis marang bathi operasional sadurunge panyusutan Kiniksa Corp|KNSA - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Kiniksa|KNSA - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan kiniksa.com|KNSA - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Kiniksa Pharmaceuticals
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:KNSA Kiniksa Pharmaceuticals, Ltd.
The monopoly status of Kiniksa Pharmaceuticals (KNSA) in the treatment of inflammatory diseases, secured by antibody patents, directly impacts the market valuation of its revenue. The current value of 4.90 reflects the ratio of market capitalization to sales volume, demonstrating how much investors are willing to pay per unit of revenue; the history of the price-to-sales multiple allows for an assessment of the balance between the asset's prestige and the risks of overvaluation.
Pesaing Kiniksa Pharmaceuticals
argenx - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (biontech.de)|Abivax Corp (ABVX) - Rega marang dodolan|ADMA Corp - Multiplikator P/S|Rasio rega marang dodolan PTGX|Immunovant Inc (IMVT) - Rasio rega marang pendapatan|Grifols - Rasio kapitalisasi pasar marang pendapatan|ADPT (Adaptive Biotech) - Multiplikator P/S|Rasio rega marang pendapatan CLDX|Multiplikator P/S AUPH|Kapitalisasi marang pendapatan biocryst.com BCRX|Vera Therapeutics - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV - Multiplikator P/S|ABCL: Rasio rega marang pendapatan|Tourmaline Bio, Inc. (TRML) - Rasio rega marang pendapatan|Rega marang dodolan precigen.com (PGEN)|PHAR (pharming.com) - Multiplikator P/S|NKTR (Nektar Therapeutics Inc.) - Kapitalisasi marang volume dodolan|Multiplikator P/S UPB|ZBIO - Rega marang dodolan|Multiplikator P/S IMNM (immunome.com)|Gossamer Bio, Inc. - Rasio rega marang pendapatan|KalVista Pharmaceuticals, Inc. - Multiplikator P/S|SEPN (Septerna) - Rasio kapitalisasi marang pendapatan|Pieris Corp (PVLA) - Rasio rega marang pendapatan|SVRA - Koefisien rega marang pendapatan|RIGL (rigel.com) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANAB (AnaptysBio, Inc.)|Multiplikator P/S ATXS|enGene Holdings Inc (ENGN) - Multiplikator rega marang pendapatan|Multiplikator P/S RAPT (RAPT Therapeutics Inc.)|JBIO (Aerovate) - Rasio rega marang dodolan|ACRS: Kapitalisasi marang pendapatan|KYTX - Multiplikator P/S|TLSA: Multiplikator P/S|Kapitalisasi marang pendapatan Cabaletta Bio, Inc|Rasio rega marang pendapatan Ventyx Biosciences, Inc|THTX: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan AVTX (Avalo Therapeutics, Inc)|Kapitalisasi marang pendapatan Eledon Pharmaceuticals ELDN|Rasio rega marang pendapatan Agenus, Inc. AGEN|Multiplikator P/S Climb Bio Inc. CLYM|ZURA - Rasio rega marang pendapatan|Rasio rega marang dodolan ATYR|ADAG (Adagene Inc.) - Kapitalisasi marang pendapatan|ImageneBio Inc (IMA) - Multiplikator P/S|Rasio rega marang pendapatan Shattuck Therapeutics|Kapitalisasi marang pendapatan equilliumbio.com (EQ)|Multiplikator P/S CNTB|Koefisien rega marang pendapatan Immunic Therapeutics|Multiplikator P/S ATRA (Atara Biotherapeutics, Inc.)|IFRX - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Rasio kapitalisasi marang pendapatan|CELU: Multiplikator P/S|INMB - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Barinthus Biotherapeutics plc|KZR: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S SABS|AKTX (Akari Therapeutics Plc) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Rasio rega marang pendapatan|GOVX: Kapitalisasi marang pendapatan|edesabiotech.com (EDSA) - Kapitalisasi marang pendapatan|IBIO: Multiplikator P/S|CARM - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan XTLB|Kapitalisasi marang pendapatan boltbio.com (BOLT)|Rasio rega marang pendapatan HCW Biologics Inc (HCWB)|Multiplikator P/S Aptevo Therapeutics, Inc. (APVO)|Rasio rega marang pendapatan aimimmuno.com AIM|Rasio kapitalisasi pasar marang pendapatan ADTX|GRI Bio Corporation - Multiplikator P/S|XORTX Corp (XRTX) - Kapitalisasi marang pendapatan|HIND (Vyome Holdings Inc.) - Kapitalisasi marang pendapatan|revbiosciences.com (REVB) - Multiplikator P/S|INDP (Indaptus Corp) - Multiplikator P/S|Kapitalisasi marang pendapatan Scinai Immunotherapeutics Ltd (SCNI)|Rasio rega marang pendapatan CalciMedica Inc (CALI)|AFMD (Affimed NV) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ALLK (Allakos Inc.)|Multiplikator P/S HOOKIPA HOOK|IGMS: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ITOS (iTeos)|OCEA: Multiplikator P/S|TCBP (TC BioPharm Ltd) - Rasio rega marang pendapatan|THRD (Third Harmonic Bio Inc) - Multiplikator P/S
